Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Anything graphite based, CCB, Zen and hopefully much more. -- Ignore unavailable to you. Want to Upgrade?

To: the Chief who wrote (2016)	2/21/2021 7:57:08 AM
From: tturner	Respond to of 2618

Chief, agree about the "BioTech" need for news. (into NK "NantKwest" and been riding the news from 7.16 to yesterdays 39.12) All news and trial related) Zen's medical use is a story that will take 2-3 years IMO. But news cycle is fast, and production cycle is just beginning. I see that story alone will push Zen up for the next 9 mo or so.

To: the Chief who wrote (2016)	2/21/2021 9:47:26 AM
From: Zengold	Respond to of 2618

Albany is dead. They have to buy GO from real producers. Even as a biotech graphene venture, the SURVIVAL RATE is 1 in 10 and that assumes they have qualified staff with experience in the industry. They really are just a manufacturing start up. The end user is really the innovator for the product and the one who makes the money. ft.com So this next hype on the latest crazy will keep naive sheep interested until it ends soon and down she goes. Zen should be market value max 30 million not 300 million . Math says 0.30 Heck, Graphenea is pumping out ink...you don't think they are looking at making a coating? Haha... The tiny rented space in the Chemisar building us only for looks....hey maybe MJ stocks will take off again ...we know the eye doctor has lots of experience pushing that sector!